You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 66 No. 4, April 2009 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Contribution
 •Online Features
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (29)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in this journal
 Topic Collections
 •Neurology
 •Multiple Sclerosis/ Demyelinating Disease
 •Dermatology
 •Dermatologic Disorders, Other
 •Drug Therapy
 •Adverse Effects
 •Drug Therapy, Other
 •Immunologic Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Regulatory T Cells Are Reduced During Anti-CD25 Antibody Treatment of Multiple Sclerosis

Unsong Oh, MD; Gregg Blevins, MD; Caitlin Griffith; Nancy Richert, MD, PhD; Dragan Maric, PhD; C. Richard Lee, MD, PhD; Henry McFarland, MD; Steven Jacobson, PhD

Arch Neurol. 2009;66(4):471-479.

Objective  Maintenance therapy with anti-CD25 antibody has emerged as a potentially useful treatment for multiple sclerosis (MS). Constitutive CD25 expression on CD4+CD25+ regulatory T cells (Treg) suggests that anti-CD25 antibody treatment may potentially target a subset of T cells that exhibit immune suppressive properties. We examined changes to CD4+CD25+ Treg in patients with MS receiving maintenance anti-CD25 monoclonal antibody treatment to determine the effect of treatment on Treg and, consequently, on immunological tolerance.

Design  Peripheral blood and cerebrospinal fluid samples obtained from a before-and-after trial of anti-CD25 antibody monotherapy were examined to compare baseline and treatment differences in CD4+CD25+ Treg.

Subjects  A total of 15 subjects with MS. One subject was withdrawn owing to an adverse effect.

Results  Sustained reduction of the frequency of CD4+CD25+ Treg was observed during treatment. Anti-CD25 antibody treatment led to evidence of impaired in vivo Treg proliferation and impaired ex vivo Treg suppression. Inflammatory MS activity was substantially reduced with treatment despite reduction of circulating Treg, and there was no correlation between changes in the frequency of Treg and changes in brain inflammatory activity. However, new-onset inflammatory disease, notably dermatitis, was also observed in a number of subjects during treatment.

Conclusion  The reduction in Treg did not negatively affect maintenance of central nervous system tolerance during anti-CD25 antibody treatment. The incidence of new-onset inflammatory disease outside of the central nervous system in a subset of patients, however, warrants further studies to examine the possibility of compartmental differences in the capacity to maintain tolerance in the setting of reduced CD4+CD25+ Treg.


Author Affiliations: Neuroimmunology Branch, National Institute of Neurological Diseases and Stroke (NINDS) (Drs Oh, Richert, McFarland, and Jacobson), NINDS FACS (fluorescence-activated cell sorter) facility (Dr Maric), and Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (Dr Lee); University of Alberta Medicine and Dentistry, Edmonton, Canada (Dr Blevins); and Grove City College, Grove City, Pennsylvania (Ms Griffith).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLE

This Month in Archives of Neurology
Arch Neurol. 2009;66(4):431-432.
FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Central Role for Interleukin-2 in Type 1 Diabetes
Hulme et al.
Diabetes 2012;61:14-22.
ABSTRACT | FULL TEXT  

CD4+FOXP3+ T Regulatory Cells in Human Autoimmunity: More Than a Numbers Game
Long and Buckner
J. Immunol. 2011;187:2061-2066.
ABSTRACT | FULL TEXT  

Pregnancy-induced fluctuations in functional T-cell subsets in multiple sclerosis patients
Neuteboom et al.
Mult Scler 2010;16:1073-1078.
ABSTRACT  

An IL-2 Paradox: Blocking CD25 on T Cells Induces IL-2-Driven Activation of CD56bright NK Cells
Martin et al.
J. Immunol. 2010;185:1311-1320.
ABSTRACT | FULL TEXT  

Monoclonal antibodies in MS: Mechanisms of action
Bielekova and Becker
Neurology 2010;74:S31-S40.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2009 American Medical Association. All Rights Reserved.